EA201491991A1 - Новая система высвобождения гидрофобных белков - Google Patents
Новая система высвобождения гидрофобных белковInfo
- Publication number
- EA201491991A1 EA201491991A1 EA201491991A EA201491991A EA201491991A1 EA 201491991 A1 EA201491991 A1 EA 201491991A1 EA 201491991 A EA201491991 A EA 201491991A EA 201491991 A EA201491991 A EA 201491991A EA 201491991 A1 EA201491991 A1 EA 201491991A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- new system
- hydrophobic proteins
- therapeutically
- prolonged
- effectiveness
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 230000002209 hydrophobic effect Effects 0.000 title abstract 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229920002674 hyaluronan Polymers 0.000 abstract 1
- 229960003160 hyaluronic acid Drugs 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2235—Secretins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L89/00—Compositions of proteins; Compositions of derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Изобретение относится к новым системам высвобождения белков, содержащим определенные амиды гиалуроновой кислоты в сочетании с терапевтически и/или биологически активными белками, преимущественно гидрофобной природы, для длительного, замедленного по времени высвобождения, которое приводит к повышению эффективности лекарственного средства и облегчает соблюдение пациентом режима лечения.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000173A ITPD20120173A1 (it) | 2012-05-31 | 2012-05-31 | "nuovo sistema di rilascio di proteine idrofobiche" |
PCT/IB2013/054477 WO2013179258A1 (en) | 2012-05-31 | 2013-05-30 | New release system of hydrophobic proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201491991A1 true EA201491991A1 (ru) | 2015-03-31 |
EA031390B1 EA031390B1 (ru) | 2018-12-28 |
Family
ID=46321311
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201491991A EA031390B1 (ru) | 2012-05-31 | 2013-05-30 | Система длительного высвобождения гидрофобных белков на основе амида гиалуроновой кислоты |
Country Status (14)
Country | Link |
---|---|
US (1) | US9731019B2 (ru) |
EP (1) | EP2854830B1 (ru) |
JP (1) | JP6247687B2 (ru) |
KR (1) | KR102090551B1 (ru) |
CN (1) | CN104349788B (ru) |
CA (1) | CA2874958C (ru) |
EA (1) | EA031390B1 (ru) |
ES (1) | ES2885764T3 (ru) |
HK (1) | HK1206993A1 (ru) |
IN (1) | IN2014KN02739A (ru) |
IT (1) | ITPD20120173A1 (ru) |
MX (1) | MX357799B (ru) |
PT (1) | PT2854830T (ru) |
WO (1) | WO2013179258A1 (ru) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT201900003887A1 (it) | 2019-03-18 | 2020-09-18 | Fidia Farm Spa | Sistemi di stabilizzazione e di rilascio controllato di farmaci instabili alla sterilizzazione |
IT201900009933A1 (it) * | 2019-06-24 | 2020-12-24 | Fidia Farm Spa | Composizioni farmaceutiche comprendenti derivati ammidici dell'acido ialuronico per uso nel trattamento di traumi ossei, in particolare in pazienti con problemi di osteopenia o osteoporosi |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US495774A (en) | 1893-04-18 | Island | ||
IT1229075B (it) | 1985-04-05 | 1991-07-17 | Fidia Farmaceutici | Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico |
NO169637C (no) | 1983-10-11 | 1992-07-22 | Fidia Spa | Fremgangsmaate for fremstilling av terapeutisk aktive hyaluronsyre-fraksjoner |
US4582865A (en) | 1984-12-06 | 1986-04-15 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
US4713448A (en) | 1985-03-12 | 1987-12-15 | Biomatrix, Inc. | Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues |
US4851521A (en) | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
IT1219587B (it) | 1988-05-13 | 1990-05-18 | Fidia Farmaceutici | Polisaccaridi carbossiilici autoreticolati |
CA1340994C (en) | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
US5827937A (en) | 1995-07-17 | 1998-10-27 | Q Med Ab | Polysaccharide gel composition |
US6096728A (en) | 1996-02-09 | 2000-08-01 | Amgen Inc. | Composition and method for treating inflammatory diseases |
ITPD980169A1 (it) * | 1998-07-06 | 2000-01-06 | Fidia Advanced Biopolymers Srl | Ammidi dell'acido ialuronico e dei suoi derivati e processo per la loro preparazione. |
IT1306679B1 (it) | 1999-06-29 | 2001-10-02 | Fidia Advanced Biopolymers Srl | Uso dei derivati dell'acido ialuronico per la preparazione dicomposizoni farmaceutiche e biomateriali per la prevenzione della |
US6645485B2 (en) | 2000-05-10 | 2003-11-11 | Allan R. Dunn | Method of treating inflammation in the joints of a body |
ES2313445T3 (es) * | 2004-12-14 | 2009-03-01 | Fidia Advanced Biopolymers S.R.L. | Procedimiento de la preparacion de armazones polimericos bi- y tri-dimensionales. |
MY139088A (en) | 2005-02-21 | 2009-08-28 | Lg Life Sciences Ltd | Sustained release composition of protein drug |
ITPD20050056A1 (it) * | 2005-03-02 | 2006-09-03 | Fidia Farmaceutici | Derivati ammidici del'acido ialuronico in osteoartrosi |
ITPD20050207A1 (it) * | 2005-07-07 | 2007-01-08 | Fidia Farmaceutici | Nuove composizioni farmaceutiche contenenti acido ialuronico e collagenas nel trattamento topico di ferite, ustioni ed ulcere |
IT1402385B1 (it) | 2010-09-09 | 2013-09-04 | Fidia Farmaceutici | Processo per la produzione di acido ialuronico in escherichia coli o bacillus subtilis |
-
2012
- 2012-05-31 IT IT000173A patent/ITPD20120173A1/it unknown
-
2013
- 2013-05-30 EP EP13737417.9A patent/EP2854830B1/en active Active
- 2013-05-30 KR KR1020147033477A patent/KR102090551B1/ko active IP Right Grant
- 2013-05-30 MX MX2014014536A patent/MX357799B/es active IP Right Grant
- 2013-05-30 WO PCT/IB2013/054477 patent/WO2013179258A1/en active Application Filing
- 2013-05-30 PT PT137374179T patent/PT2854830T/pt unknown
- 2013-05-30 IN IN2739KON2014 patent/IN2014KN02739A/en unknown
- 2013-05-30 JP JP2015514665A patent/JP6247687B2/ja active Active
- 2013-05-30 US US14/404,138 patent/US9731019B2/en active Active
- 2013-05-30 EA EA201491991A patent/EA031390B1/ru not_active IP Right Cessation
- 2013-05-30 CA CA2874958A patent/CA2874958C/en active Active
- 2013-05-30 CN CN201380028007.8A patent/CN104349788B/zh active Active
- 2013-05-30 ES ES13737417T patent/ES2885764T3/es active Active
-
2015
- 2015-08-10 HK HK15107694.7A patent/HK1206993A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
KR102090551B1 (ko) | 2020-03-19 |
EA031390B1 (ru) | 2018-12-28 |
IN2014KN02739A (ru) | 2015-05-08 |
JP2015518042A (ja) | 2015-06-25 |
ES2885764T3 (es) | 2021-12-15 |
CA2874958A1 (en) | 2013-12-05 |
US9731019B2 (en) | 2017-08-15 |
CN104349788A (zh) | 2015-02-11 |
ITPD20120173A1 (it) | 2013-12-01 |
MX357799B (es) | 2018-07-25 |
US20150290326A1 (en) | 2015-10-15 |
EP2854830B1 (en) | 2021-06-30 |
MX2014014536A (es) | 2015-02-24 |
EP2854830A1 (en) | 2015-04-08 |
CN104349788B (zh) | 2017-07-28 |
WO2013179258A1 (en) | 2013-12-05 |
JP6247687B2 (ja) | 2017-12-13 |
KR20150016951A (ko) | 2015-02-13 |
CA2874958C (en) | 2023-02-14 |
HK1206993A1 (en) | 2016-01-22 |
PT2854830T (pt) | 2021-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124729T1 (el) | Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου | |
MX2017007641A (es) | Conjugados de anticuerpo-farmaco con inhibidores de bcl-xl permeables en las celulas. | |
PH12014501702A1 (en) | Imidazopyrrolidinone compounds | |
EA201390821A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты и их применение | |
EA201290590A1 (ru) | Модифицированные туберкулезные антигены | |
EA201491856A1 (ru) | Терапевтическое применение белков фактора роста фибробластов 21 | |
SG10201811186XA (en) | Purification of proteins | |
EA201300137A1 (ru) | Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний, связанных с нейродегенеративными зоболеваниями | |
BR112015006731A2 (pt) | combinações e usos das mesmas | |
HK1222331A1 (zh) | 修飾的繆勒抑制物質 蛋白及其用於疾病治療的用途 | |
EA201390745A1 (ru) | Активируемая пользователем автономная выполненная в едином корпусе система доставки лекарственного средства посредством ионофореза | |
EA201190168A1 (ru) | Терапевтические применения фракций мастиковой смолы | |
EA201291211A1 (ru) | Фармацевтические композиции, содержащие гидроморфон и налоксон | |
EA201300132A1 (ru) | Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич | |
EP2552462A4 (en) | CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTIC USE | |
AU2012280776B2 (en) | Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases | |
EA201491991A1 (ru) | Новая система высвобождения гидрофобных белков | |
CY1117968T1 (el) | Θεραπευτικη χρηση της πρωτεϊνης β2-μικροσφαιρινη | |
ES2396764A1 (es) | FÁRMACOS INHIBIDORES DE p38 Y APLICACIONES. | |
UA112488C2 (uk) | Три(гетеро)арилпіразоли і їх застосування | |
MX2022001772A (es) | Formulaciones de isotretinoina y usos y metodos de las mismas. | |
PE20160848A1 (es) | Nuevo compuesto para el tratamiento de hipoglicemia severa | |
EP2578232A4 (en) | TREATMENT FOR AUTOIMMUN DISEASES AND ALLERGIC DISEASES | |
GB2558494B (en) | Protein nanostructure based drug delivery system for the delivery of therapeutic agents to the anterior segment of the eye | |
MX2014008194A (es) | Cefovecina util en el tratamiento de la enfermedad de lyme. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): TJ TM |